Ebi Hiromichi

エビヒロミチ | Ebi Hiromichi

Affiliation and department：
Job title： Division Head
Other affiliations (1)：

愛知県がんセンター中央病院個別化医療センター副センター長

Research field (1)： Tumor diagnostics and therapeutics

Research theme for competitive and other funds (6)：

2020 - 2023 BRAF変異腫瘍の臓器多様性の解明とtumor agonistic治療への応用
2016 - 2019 Development of target therapy against KRAS mutant lung cancer stratified by EMT status.
2016 - 2019 Develop novel therapeutics against KRAS mutant cancer by regulating PI3K and ERK signal(Fostering Joint International Research)
2014 - 2016 Development of treatment strategy against KRAS mutant cancer by targeting PI3K and ERK
2012 - 2015 Study to overcome metastasis and targeted drug-resistance of lung cancer

Show all

Papers (81)：

Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer Science. 2024
Akimitsu Maeda, Hitoshi Ando, Kei Irie, Naoya Hashimoto, Jun-Ichi Morishige, Shoji Fukushima, Hiromichi Ebi, Kosaku Uchida, Hiroji Iwata, Masataka Sawaki. Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). Anticancer research. 2023. 43. 3. 1283-1289
Jinyang Cai, Sheeba Jacob, Richard Kurupi, Krista M Dalton, Colin Coon, Patricia Greninger, Regina K Egan, Giovanna T Stein, Ellen Murchie, Joseph McClanaghan, et al. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell reports. 2022. 40. 4. 111095-111095
Akimitsu Maeda, Hitoshi Ando, Kei Irie, Naoya Hashimoto, Jun-Ichi Morishige, Shoji Fukushima, Akira Okada, Hiromichi Ebi, Masahide Matsuzaki, Hiroji Iwata, et al. Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European journal of clinical pharmacology. 2022. 78. 8. 1239-1247
Fumie Nakasuka, Sho Tabata, Takeharu Sakamoto, Akiyoshi Hirayama, Hiromichi Ebi, Tadaaki Yamada, Ko Umetsu, Maki Ohishi, Ayano Ueno, Hisatsugu Goto, et al. TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. Communications Biology. 2021. 4. 1

ｍore...

MISC (4)：

Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Nobuhisa Matsuhashi, et al. Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC. ANNALS OF ONCOLOGY. 2022. 33. S479-S479
大坪公士郎, 足立雄太, 谷本梓, 西山明宏, 竹内伸司, 衣斐寛倫, 矢野聖二. 当科におけるFOLFIRINOX療法、GEM+nab-PTX療法導入後の膵癌化学療法の治療成績. 日本内科学会雑誌. 2017. 106. Suppl. 238-238
Development of drugs that overcome T790M-mutant EGFR in NSCLC. 2014. 13. 3. 376-383
Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Takayuki Nakagawa, Shigeki Nanjo, Hiromichi Ebi, Takahiro Nakamura, Kunio Matsumoto, Manabu Soda, Hiroyuki Mano, et al. PARACRINE RECEPTOR LIGANDS ACTIVATE BYPASS TRACTS AND CAUSE ALK INHIBITOR RESISTANCE IN EML4-ALK LUNG CANCER CELLS. JOURNAL OF THORACIC ONCOLOGY. 2012. 7. 11. S455-S455

Professional career (1)：

MDPhD

Work history (9)：

2018/04 - 現在 Aichi Cancer Center, Research Institute
2018/02 - 2018/03 愛知県がんセンター腫瘍病理学部部長
2016/03 - 2018/01 Kanazawa University Cancer Research Institute
2012/06 - 2016/02 Kanazawa University Cancer Research Institute
2008/09 - 2012/05 マサチューセッツ総合病院がんセンター博士研究員

Show all

Awards (2)：

2015/09 - Japan Cancer Association Incitement Award
2007 - International Association for the Study of Lung Cancer Fellowship and Young Investigator Award

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page